BR112013001489A2 - produto farmacêutico compreendendo 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino-6-[(5-isopropoxi-1h-pirazol-3-il)amino]-piridino-3-carbonitrila - Google Patents

produto farmacêutico compreendendo 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino-6-[(5-isopropoxi-1h-pirazol-3-il)amino]-piridino-3-carbonitrila

Info

Publication number
BR112013001489A2
BR112013001489A2 BR112013001489A BR112013001489A BR112013001489A2 BR 112013001489 A2 BR112013001489 A2 BR 112013001489A2 BR 112013001489 A BR112013001489 A BR 112013001489A BR 112013001489 A BR112013001489 A BR 112013001489A BR 112013001489 A2 BR112013001489 A2 BR 112013001489A2
Authority
BR
Brazil
Prior art keywords
fluoro
amino
carbonitrile
pyrazol
isopropoxy
Prior art date
Application number
BR112013001489A
Other languages
English (en)
Inventor
Fuller Emily
Janin Armelle
Macfaul Philip
Nash Ian
Pugh Rachel
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44511084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013001489(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112013001489A2 publication Critical patent/BR112013001489A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112013001489A 2010-07-19 2011-07-19 produto farmacêutico compreendendo 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino-6-[(5-isopropoxi-1h-pirazol-3-il)amino]-piridino-3-carbonitrila BR112013001489A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36540710P 2010-07-19 2010-07-19
PCT/GB2011/051357 WO2012010883A2 (en) 2010-07-19 2011-07-19 Pharmaceutical depot for 5-fluoro-2 [ [ (1s) -1- (5-fluoro-2-pyridyl)ethyl]amino]-6-[(5-isopropoxy-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile

Publications (1)

Publication Number Publication Date
BR112013001489A2 true BR112013001489A2 (pt) 2016-05-31

Family

ID=44511084

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013001489A BR112013001489A2 (pt) 2010-07-19 2011-07-19 produto farmacêutico compreendendo 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino-6-[(5-isopropoxi-1h-pirazol-3-il)amino]-piridino-3-carbonitrila

Country Status (19)

Country Link
US (2) US20120022110A1 (pt)
EP (1) EP2595608A2 (pt)
JP (1) JP2013535443A (pt)
KR (1) KR20130137592A (pt)
CN (1) CN103108627A (pt)
AR (1) AR082291A1 (pt)
AU (1) AU2011281323A1 (pt)
BR (1) BR112013001489A2 (pt)
CA (1) CA2804725A1 (pt)
CL (1) CL2013000174A1 (pt)
CO (1) CO6670578A2 (pt)
EC (1) ECSP13012447A (pt)
MX (1) MX2013000774A (pt)
RU (1) RU2013104639A (pt)
SG (1) SG186929A1 (pt)
TW (1) TW201208685A (pt)
UY (1) UY33517A (pt)
WO (1) WO2012010883A2 (pt)
ZA (1) ZA201301246B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108871607B (zh) 2018-08-13 2020-01-03 太原理工大学 一种面向分布式光纤拉曼传感器的高精度温度解调方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
KR100367144B1 (ko) * 1997-07-02 2003-01-14 유로-셀티크 소시에떼 아노뉨 관절과 체강(ｂｏｄｙ ｓｐａｃｅ)내에서 연장된 마취
CN100528224C (zh) * 2004-09-27 2009-08-19 中国人民解放军军事医学科学院毒物药物研究所 含干扰素α-1b的注射用缓释微球及其制备方法
CN1631362A (zh) * 2004-11-26 2005-06-29 中国科学院上海药物研究所 一种抗肿瘤控释组合物及其制备方法
US20060140988A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Visco-supplement composition and methods
CN1308034C (zh) * 2004-12-27 2007-04-04 中山大学 一种干扰素聚乳酸－羟乙酸共聚物plga微球的制备方法
ES2375735T3 (es) 2005-02-04 2012-03-05 Astrazeneca Ab Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas.
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
CN100457187C (zh) * 2006-11-10 2009-02-04 中国人民解放军第二军医大学 Vegf缓释注射微球支架及其制备方法和用途
US8153112B2 (en) * 2007-08-03 2012-04-10 Warsaw Orthopedic, Inc. Compositions and methods for treating cavity conditions
US20090281150A1 (en) * 2008-04-09 2009-11-12 Nicola Frances Bateman Compound 249

Also Published As

Publication number Publication date
JP2013535443A (ja) 2013-09-12
KR20130137592A (ko) 2013-12-17
SG186929A1 (en) 2013-02-28
EP2595608A2 (en) 2013-05-29
WO2012010883A3 (en) 2012-09-07
MX2013000774A (es) 2013-03-22
CO6670578A2 (es) 2013-05-15
RU2013104639A (ru) 2014-08-27
AU2011281323A1 (en) 2013-02-28
TW201208685A (en) 2012-03-01
AR082291A1 (es) 2012-11-28
CA2804725A1 (en) 2012-01-26
ZA201301246B (en) 2014-05-28
US20120022110A1 (en) 2012-01-26
CL2013000174A1 (es) 2013-03-08
WO2012010883A2 (en) 2012-01-26
CN103108627A (zh) 2013-05-15
ECSP13012447A (es) 2013-03-28
UY33517A (es) 2012-02-29
US20140045895A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
IL259921B (en) A new stabilizing factor for pharmaceutical proteins
HK1259250A1 (zh) 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的藥物製劑
IL253870B (en) Certain amino-pyrimidines and pharmaceutical preparations containing them
ZA201300920B (en) Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same
IL224976A (en) Converted history of 1h - indazole and a pharmaceutical preparation containing them
HK1206360A1 (en) (aza)indolizine derivative and pharmaceutical use thereof ()
HK1169960A1 (en) Pharmaceutical formulation
IL211018A (en) Inhibitors, processes for making them, medicinal preparations containing them and their use
EP2588127A4 (en) DIPEPTIDE-NETWORKED MEDICAL ACTIVE SUBSTANCES
EP2554169A4 (en) PHARMACEUTICAL PREPARATION COMPRISING A PHENYLALANINE DERIVATIVE
EP2402305A4 (en) LOXOPROFEN DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME
GB2486567B (en) Pharmaceutical formulation
EP2618816A4 (en) AEROSOL COMPOSITION FOR THE ADMINISTRATION OF MEDICAMENTS
IL226003A (en) Terence of trans - 2 - Decanoic acid and its pharmacist
HK1198939A1 (en) Pharmaceutical preparation comprising brexpiprazole and substituted beta - cyclodextrin brexpiprazole -
EP2306998A4 (en) PHARMACEUTICAL FORMULATION
EP2560614A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR ADMINISTRATION
EP2532665A4 (en) Benzimidazole derivatives and pharmaceutical compositions thereof and uses thereof
IL221087A (en) Pharmacy or nutritional composition
EP2322505A4 (en) 1-ADAMANTYLAZETIDIN-2-ON DERIVATIVE, PREPARATION THEREOF AND PHARMACEUTICAL PREPARATION THEREWITH
HRP20141173T1 (hr) Medikament koji sadrži miramistin
IL223707A0 (en) N-hydroxyformamide derivative and medicament containing same
EP2471782A4 (en) NEW SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
BR112013001489A2 (pt) produto farmacêutico compreendendo 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino-6-[(5-isopropoxi-1h-pirazol-3-il)amino]-piridino-3-carbonitrila
ZA201403735B (en) Pharmaceutical formulations comprising atorvastatin and glimepiride

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]